Nexalin Technology NXL 深 滬
已收盤 08-07 16:00:00 美东时间
0.3529
+0.014
+4.22%
華盛通- 最 高0.3639
- 今 開0.35
- 成交量 20.38万股
- 最 低 0.335
- 昨 收 0.3386
- 總市值 776.78万
- 52周最高 2.00
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 0.305
- 委 比 -96.08%
- 總股本 2201.13万
- 歷史最高 4.4899
- 量 比 1.29
- 振 幅 8.54%
- 歷史最低 0.2528
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nexalin Expands and Extends Houston Headquarters Lease Commitment
Nexalin Technology, Inc. ( ($NXL) ) has shared an announcement. On July 28, 202...
07-30 05:49
Nexalin Appeals Nasdaq Delisting Following Compliance Shortfalls
An announcement from Nexalin Technology, Inc. ( ($NXL) ) is now available. On J...
07-28 05:50
Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework
The latest announcement is out from Nexalin Technology, Inc. ( ($NXL) ). On Jun...
06-18 06:57
Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life Data to be presented include 77.8% anxiety response rate at end of treatment, durable benefits maintained at 8-week follow-up an...
06-16 21:18
Nexalin Technology Announces New U.S. Patent Covering Dynamic Frequency Deep-Brain Neurostimulation For Anxiety, Depression, And Insomnia Treatment
The United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: "Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia."The newly issued
06-04 22:03
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
Nexalin Technology has been granted U.S. Patent No. 12,629,519, providing intellectual property protection until 2042 for its dynamic frequency stimulation method targeting anxiety, depression, and insomnia. The patent strengthens Nexalin's leadership in non-invasive deep-brain neurostimulation and supports its HALO™ Clarity and NeuroCare™ strategies. The technology aims to address significant unmet medical needs through a drug-free, at-home trea...
06-04 14:00
Nexalin Technology Acquires Digital Health Platform PONM From GreenLight Ventures; Financial Terms Not Disclosed
Through the transaction, Nexalin has secured ownership of PONM and an exclusive license to the proprietary software features developed for the HALO™ program, including AI-integrated remote patient monitoring,
05-19 20:37
Nexalin To Begin Enrollment For Pivotal HALO Clarity Insomnia Trial In Q2 2026; Targeting FDA De Novo Pathway
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced it has entered into agreements to
04-22 21:36
Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline results from ongoing Phase 2/3 trial.
04-13 17:27
